Bullfrog Ai Holdings, Inc. (BFRGW) Stock Price & Analysis

Bullfrog Ai Holdings, Inc. (BFRGW) fell 1.38% to USD 0.1 as of September 9, 2026 at 14:55 UTC, according to Nexqual real-time market data.

BFRGW last closed at USD 0.1; the session ranged USD 0.1–0.1 on volume of 201 shares. Market capitalization is —, with a 52-week range of USD 0.1–0.1 (NCM). Source: Nexqual, September 9, 2026 at 14:55 UTC.

Key Statistics (as of September 9, 2026 at 14:55 UTC)

Analyst Ratings (BFRGW)

Wall Street analysts rate BFRGW "None", per Nexqual as of September 9, 2026 at 14:55 UTC.

Earnings (BFRGW)

Source: Nexqual, September 9, 2026 at 14:55 UTC.

Financial Health Score (BFRGW)

Nexqual rates Bullfrog Ai Holdings, Inc.'s overall financial health "Mixed" across five dimensions, as of September 9, 2026 at 14:55 UTC.

Major Backers & Investors (BFRGW)

Notable institutional backers of Bullfrog Ai Holdings, Inc. include Clear Street Group Inc., Anson Funds Management LP, L1 Global Manager Pty Ltd, according to Nexqual as of September 9, 2026 at 14:55 UTC.

Active Investors

Source: Nexqual, September 9, 2026 at 14:55 UTC.

From Bullfrog Ai Holdings, Inc.'s Latest SEC 10-K Filing (filed 2026-03-19)

Key Strengths & Strategy (as disclosed to the SEC)

• The license agreement also contains milestone payments for clinical development through the approval of a New Drug Application ("NDA") and commercialization.   Aggregate future milestone costs could reach $860,000 if the drug successfully completes clinical trials and is the subject of an NDA to the United States FDA.
• We provide the customer with an analysis of large complex data sets using our proprietary AI/ML platform called bfLEAP™.
• Our platform technology, bfLEAP™, is an analytical AI/ML platform derived from technology developed at The Johns Hopkins University Applied Physics Laboratory ("JHU-APL"), which is able to surmount the challenges of scalability and flexibility currently hindering researchers and clinicians by providing a more precise 1 , multi-dimensional understanding of their data.
• This strategy will include strategic partnerships, collaborations, and relationships along the entire drug development value chain, as well as acquisitions of the rights to developing failed drugs and possibly the underlying companies.   To date, we have not conducted clinical trials on any pharmaceutical drugs and our platform has not been used to identify a drug candidate that has received regulatory approval for commercialization.

Partnerships

• The financial terms of the new license agreement replaces the original terms from the 2018 License Agreement and are not duplicative.   In May 2023, we entered into Amendment Number 1 of the July 2022 License Agreement with JHU-APL whereby we gained access to certain improvements including additional patents and know-how in exchange for a series of payments totaling $275,000.
• In November 2021, we amended our license agreement with JHU-APL to include additional advanced AI technology.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 9, 2026 at 14:55 UTC. This page is informational and not investment advice.